Abstract:Circulating single-molecule amplification and resequencing technology (cSMART) based on next-generation sequencing is highly sensitive, accurate and quantificational. The purpose of this study is to detect the status of 9 driver genes in Chinese NSCLC patients using cSMART and analyze the associations of gene status, clinical characteristics and prognosis. The tissue or plasma samples of 85 patients diagnosed NSCLC from Hangzhou First People's Hospital were collected. EGFR, KRAS, ALK, ROS1, PIK3CA, c-MET, RET, BRAF and HER2 genes were combined detection using cSMART. The association between gene status and clinical characteristics was analyzed by chi-square test and Fisher's exact. Kaplan-Meier survival curves were plotted for overall survival (OS) and analyzed with the log-rank test. Cox proportional hazards regression was used for multivariate analysis. Amongst 85 NSCLC patients, EGFR mutations were more frequent (57.6%), followed by KRAS mutation (18.8%), ALK mutation (10.6%), ALK fusion (9.4%), MET mutation (9.4%), PI3KCA mutation (8.2%), ROS1 fusion (3.5%), BRAF mutation (1.2%), RET fusion (1.2%) and HER2 mutation was not found. Furthermore, the abundances of gene mutation were relatively low. The EGFR mutation rate was higher in patients with adenocarcinoma histology than in those with squamous carcinoma histology (P=0.03). T790M mutation was more common in patients with a history of TKI treatment (P<0.01) and acquired T790M mutation was often accompanied by the original sensitive mutation (P<0.01). ALK fusion was more easily detected in tissue sample. All 8 MET gene exon14 skippings were found in adenocarcinoma histology and this gene alteration often happened after TKI treatment (P=0.02). OS was significantly improved in the EGFR mutation group compared with the wild group (median 32m vs 19m) (P=0.05). No significant survival difference between KRAS mutation and wild group was found (P>0.05). Among EGFR wild advanced NSCLC patients, the median OS of KRAS mutation group was 13 months while that of wild group was 26 months, but there was no significant difference (P>0.05). Multivariant analyzes showed gender, TKI treatment history and smoking history were independent prognostic factors in NSCLC (P<0.05). EGFR mutation is the most common driver gene in Chinese NSCLC, especially in adenocarcinoma patients, which often occurs in exon 19, 20 and 21 region. Then followed by KRAS mutation, it mostly occurs in exon 2. MET gene exon14 skipping is common in patients with adenocarcinoma or post-TKI treatment, which may be related to TKI resistance. Gender, smoking history and TKI treatment history could be independent prognostic factors in NSCLC.

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Clinical Features and Therapeutic Options in Non‐small Cell Lung Cancer Patients with Concomitant Mutations of EGFR, ALK, ROS1, KRAS or BRAF

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Concurrent Oncogene Mutation Profile in Chinese Patients with Stage Ib Lung Adenocarcinoma.

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

Characterization of Distinct Types of KRAS Mutation and Its Impact on First-Line Platinum-Based Chemotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer (NSCLC)

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Genomic Characteristics of Driver Genes in Chinese Patients with Non‐small Cell Lung Cancer

Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics

Genomic Profiling of Driver Gene Mutations in Chinese Patients with Non-Small Cell Lung Cancer

Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.

The Co-Mutation of EGFR and Tumor-Related Genes Leads to a Worse Prognosis and a Higher Level of Tumor Mutational Burden in Chinese Non-Small Cell Lung Cancer Patients

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

P3.02-040 Driver Gene Detection in Chinese NSCLC Patients Using Csmart and Prognosis Analysis

Association Between Certain Non–small Cell Lung Cancer Driver Mutations and Predictive Markers for Chemotherapy or Programmed Death‐ligand 1 Inhibition

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

Driver Gene Alterations Profiling of Chinese Non‐small Cell Lung Cancer and the Effects of Co‐occurring Alterations on Immunotherapy